Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma

Title: Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma NCT ID: NCT07501117 Phase: PHASE1 Status: NOT_YET_RECRUITING Sponsor: Inge Marie Svane Conditions: Uveal Melanoma Interventions: Nivolumab & Ipilimumab Enrollment: 15 ESTIMATED Summary: The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is: \- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.